Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Inclusion Criteria: * Intermediate risk prostate cancer patients will be eligible for this study. Intermediate risk grouping will be assessed per NCCN guidelines as: * Pathologically-proven diagnosis of prostate adenocarcinoma * PSA 10-20ng/mL or * Gleason =7 or * Clinical stage T2b/c * Clinical stage T2b/c Additionally, patients will be required to meet the following criteria * Age ≥18 * KPS≥70 * Prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). For patients with a prostate volume between 50-60ccs, hormone therapy will be at the discretion of the physician. * International Prostate Symptom Score ≤15 Exclusion Criteria: * Prior prostate surgery (including TURP) * Prior history of chronic prostatitis or urethral stricture * Inflammatory bowel disease * Prior history of pelvic radiotherapy * Unable to give informed consent * Metastatic disease.